Toric IOL implantation in cataract patients

Article

In this article, Dr Bauer reveals the preliminary results of cataract surgerywith the AcrySof ReSTOR IQ toric multifocal IOL

Dr Bauer revealed the preliminary findings of cataract surgery with the AcrySof ReSTOR toric lens (Alcon Laboratories, Fort Worth, Texas, USA) during one of Saturday's sessions at this year's ESCRS meeting in Vienna, Austria. This lens combines the features of the Acrysof Restor IOL with the Acrysof Toric IOL, which is ideal for cataract patients with astigmatism.

The study

Implantation of the AcrySof ReSTOR toric lens was performed during routine cataract surgery in patients with a corneal astigmatism of greater than 1 D. "The lens, is an aspheric diffractive/refractive multifocal toric IOL with a spherical range of +10 to +30, cylinder range of +1 to +3 and a near add of +3.0 D," he continued.

"Within our study group of 14 eyes there were four that were hyperopic and outside of the spherical range because of their short axial length," he added. "We planned for implantation of the ReSTOR toric IOL first and then LASIK afterwards."

The outcome parameters of the study included uncorrected distance visual acuity (UDVA), uncorrected near visual acuity (UNVA) and residual refractive cylinder.

Refractive results and visual outcomes

At 3-months follow-up the residual refractive cylinder was -0.45 D, Dr Bauer noted. "We found that more than 75% of our study group had a refractive cylinder smaller than 0.75 D and more than 80% of eyes had an uncorrected distance Snellen visual acuity of 0.8 or more," he added.

"In 10 eyes the post-operative uncorrected distance visual acuity was 0.9 and the uncorrected near visual acuity was 0.7, approximately equal to J2," Dr Bauer said.

Conclusion

This study demonstrated that through using this aspheric diffractive/refractive multifocal toric IOL in patients with cataract and corneal astigmatism there is a possibility to achieve good results in both distance and near visual acuity.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.